PExA Exhibits at Europe’s Largest Lung Congress
PExA AB (publ) (“PExA” or the “Company”) is participating for the second consecutive year at the European Respiratory Society (ERS) congress, one of the world’s largest congresses in respiratory medicine, held this year in Vienna. Five scientific papers, which include results based on the use of PExA’s technology, have been accepted for presentation at the congress.
The ERS congress is a global meeting place for researchers, clinicians, and companies in the field of respiratory medicine, offering a unique opportunity to network and exchange knowledge. PExA’s participation in this congress is a key part of the Company’s strategy to strengthen its position as a leading player in lung research. After a successful participation at last year’s ERS congress in Italy, the Company has decided to double the size of its booth this year for even better exposure and opportunities to showcase its world-unique technology.
This year, five scientific papers involving the use of PExA’s technology have been accepted into the scientific program at ERS 2024. These papers will be presented by researchers and cover a wide range of innovative applications in the field. The Company sees this as recognition of the significance and potential of PExA’s technology in global research and development of diagnostics and treatment for lung diseases.
The following scientific papers involving results from the use of PExA’s technology will be presented:
- Feasibility of miRNA Detection in Particles in Exhaled Air (PExA) using a multiplexed RT-PCR Method
- Compositional changes in pulmonary surfactant among welding fume exposed associated with oxidative stress and inflammation
- Changes in the pulmonary surfactant in patients with mild COVID-19
- Exposure to air pollutants and effects on the small airway lining fluid in allergic Asthma
- Phospholipid composition of the respiratory tract lining fluid (RTLF) in subjects with Asthma and COPD
Tomas Gustafsson, CEO of PExA, comments:
- Our presence at one of the world’s largest lung congresses is not only an opportunity to demonstrate our products but also to actively contribute to advancements in respiratory medicine. I am proud that several of our customers have been accepted to present a total of five scientific papers, as this highlights our strong commitment to innovation and collaboration in lung research. I am also very pleased with our increased exposure, as we are doubling the size of our booth this year and have secured an excellent location. I would like to take this opportunity to invite all attendees to visit our booth during the congress. Here, visitors will be able to meet our team, learn more about our latest advancements, and get informed about how our technology can support research and development in respiratory medicine.
For further information, please contact:
Tomas Gustafsson, Email: info@pexa.se
About PExA AB:
PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.